<?xml version="1.0" encoding="utf-8"?> <feed xmlns:dc="http://dublincore.org/documents/dcmi-namespace/" xmlns:media="http://search.yahoo.com/mrss/" xmlns="http://www.w3.org/2005/Atom"> <title type="text">Capwell Communications</title> <subtitle type="text">Contains the last 20 releases</subtitle> <id>uuid:102356e7-63ad-4922-973d-a792f8b7e881;id=916</id> <rights type="text">Copyright 2019, Capwell Communications</rights> <updated>2019-09-18T13:05:00Z</updated> <author> <name>newsdesk@globenewswire.com (NewsDesk)</name> <uri>http://www.globenewswire.com/LegacyRss?Length=4</uri> <email>newsdesk@globenewswire.com</email> </author> <link rel="alternate" href="https://www.globenewswire.com/atomfeed/organization/22ySqzs1Gevg3QucSIfmRQ==" /> <link rel="self" href="https://www.globenewswire.com/atomfeed/organization/22ySqzs1Gevg3QucSIfmRQ==" /> <entry> <id>https://www.globenewswire.com/news-release/2019/09/18/1917418/0/en/neurolens-Introduces-New-Offerings-at-Vision-Expo-West.html</id> <title type="text">neurolens Introduces New Offerings at Vision Expo West</title> <published>2019-09-18T13:05:00Z</published> <updated>2024-11-25T22:48:14Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2019/09/18/1917418/0/en/neurolens-Introduces-New-Offerings-at-Vision-Expo-West.html" /> <content type="html"><![CDATA[Streamlined Software and Patient Financing Support National Expansion of the neurolens Treatment for Private Practice Optometry <pre>Streamlined Software and Patient Financing Support National Expansion of the neurolens Treatment for Private Practice Optometry</pre>]]></content> <dc:identifier>1917418</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Capwell Communications</dc:contributor> <dc:modified>Wed, 18 Sep 2019 13:05 GMT</dc:modified> <dc:subject>Company Announcement</dc:subject> <dc:keyword>VEW</dc:keyword> <dc:keyword>Vision Expo West</dc:keyword> <dc:keyword>neurolens</dc:keyword> <dc:keyword>optometry</dc:keyword> <dc:keyword>eye care</dc:keyword> </entry> <entry> <id>https://www.globenewswire.com/news-release/2017/10/31/1221131/0/en/Ivantis-Completes-Pre-Market-Approval-Submission-for-the-Hydrus-TM-Microstent-for-Minimally-Invasive-Glaucoma-Surgery-MIGS.html</id> <title type="text">Ivantis Completes Pre-Market Approval Submission for the Hydrus(TM) Microstent for Minimally Invasive Glaucoma Surgery (MIGS) </title> <published>2017-10-31T13:05:00Z</published> <updated>2024-11-25T22:48:14Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2017/10/31/1221131/0/en/Ivantis-Completes-Pre-Market-Approval-Submission-for-the-Hydrus-TM-Microstent-for-Minimally-Invasive-Glaucoma-Surgery-MIGS.html" /> <content type="html"><![CDATA[<p>IRVINE, CA--(Marketwired - Oct 31, 2017) - <a rel="nofollow" href="http://www.ivantisinc.com/" title="Ivantis Inc.,">Ivantis Inc.,</a> developer of the novel <a rel="nofollow" href="http://ivantisinc.com/hydrus-microstent.php" title="Hydrus™ Microstent">Hydrus™ Microstent</a>, a device designed to lower eye pressure for open-angle glaucoma patients, announced today that it has submitted its final Pre-Market-Approval (PMA) module to the U.S. Food and Drug Administration (FDA) for market approval.</p>]]></content> <dc:identifier>1221131</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Ivantis Inc.</dc:contributor> <dc:modified>Tue, 05 Dec 2017 01:37 GMT</dc:modified> </entry> <entry> <id>https://www.globenewswire.com/news-release/2017/05/25/1221129/0/en/Clinical-Trial-Evaluating-the-Effect-of-Prolact-CR-R-on-Length-of-Stay-and-Bronchopulmonary-Dysplasia-Among-Very-Low-Birth-Weight-Infants-Surpasses-the-Halfway-Point.html</id> <title type="text">Clinical Trial Evaluating the Effect of Prolact CR(R) on Length of Stay and Bronchopulmonary Dysplasia Among Very Low Birth Weight Infants Surpasses the Halfway Point </title> <published>2017-05-25T13:05:00Z</published> <updated>2024-11-25T22:48:14Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2017/05/25/1221129/0/en/Clinical-Trial-Evaluating-the-Effect-of-Prolact-CR-R-on-Length-of-Stay-and-Bronchopulmonary-Dysplasia-Among-Very-Low-Birth-Weight-Infants-Surpasses-the-Halfway-Point.html" /> <content type="html"><![CDATA[<p>DUARTE, CA--(Marketwired - May 25, 2017) - <a rel="nofollow" href="http://www.prolacta.com/" title="Prolacta Bioscience">Prolacta Bioscience</a>®, the pioneer in human milk-based neonatal nutritional products for premature infants, announced today that it passed the halfway point in a clinical trial evaluating the effect of adding <a rel="nofollow" href="http://www.prolacta.com/human-milk-caloric-fortifier" title="Prolact CR®">Prolact CR®</a>, a caloric fortifier made from 100 percent human milk cream, to an exclusive human milk-based diet (EHMD)<sup>1</sup> for very low birth weight (VLBW) premature infants. The study is evaluating the length of stay and incidence of bronchopulmonary dysplasia (BPD) and has enrolled 127 of the 210 participants weighing between 500 and 1,250g (1 lb 1 oz to 2 lbs 12 oz).</p>]]></content> <dc:identifier>1221129</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Prolacta Bioscience</dc:contributor> <dc:modified>Tue, 05 Dec 2017 01:37 GMT</dc:modified> </entry> <entry> <id>https://www.globenewswire.com/news-release/2017/05/15/1221126/0/en/ConcertoHealth-R-Appoints-Julie-Webb-Hopkins-Chief-Human-Resources-Officer.html</id> <title type="text">ConcertoHealth(R) Appoints Julie Webb-Hopkins Chief Human Resources Officer </title> <published>2017-05-15T13:05:00Z</published> <updated>2024-11-25T22:48:14Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2017/05/15/1221126/0/en/ConcertoHealth-R-Appoints-Julie-Webb-Hopkins-Chief-Human-Resources-Officer.html" /> <content type="html"><![CDATA[<p>IRVINE, CA--(Marketwired - May 15, 2017) - <a rel="nofollow" href="http://www.concertohealthcare.com/" title="ConcertoHealth">ConcertoHealth</a>, the leading provider of specialized primary care and supporting clinical services for complex, frail, elderly and dual-eligible patients, announced the appointment of Julie M. Webb-Hopkins as Chief Human Resources Officer (CHRO), effective April 17. Webb-Hopkins brings more than 20 years of experience in human resources (HR) and organizational development. </p>]]></content> <dc:identifier>1221126</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>ConcertoHealth</dc:contributor> <dc:modified>Tue, 05 Dec 2017 01:37 GMT</dc:modified> </entry> <entry> <id>https://www.globenewswire.com/news-release/2017/05/15/1221127/0/en/Prolacta-Bioscience-R-Applauds-New-York-Gov-Cuomo-Assemblywoman-Solages-Senator-Hannon-State-Lawmakers-for-Providing-Access-to-an-Exclusive-Human-Milk-Diet-for-Extremely-Premature-.html</id> <title type="text">Prolacta Bioscience(R) Applauds New York Gov. Cuomo, Assemblywoman Solages, Senator Hannon & State Lawmakers for Providing Access to an Exclusive Human Milk Diet for Extremely Premature Infants </title> <published>2017-05-15T13:05:00Z</published> <updated>2024-11-25T22:48:14Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2017/05/15/1221127/0/en/Prolacta-Bioscience-R-Applauds-New-York-Gov-Cuomo-Assemblywoman-Solages-Senator-Hannon-State-Lawmakers-for-Providing-Access-to-an-Exclusive-Human-Milk-Diet-for-Extremely-Premature-.html" /> <content type="html"><![CDATA[<p>DUARTE, CA--(Marketwired - May 15, 2017) - <a rel="nofollow" href="http://www.prolacta.com/" title="Prolacta Bioscience">Prolacta Bioscience</a>, the pioneer in human milk-based nutritional products for premature infants, applauds Governor Andrew Cuomo, Assemblywoman Michaelle C. Solages, D-22, Senator Kemp Hannon, R-6, and the entire New York State Legislature for expanding Medicaid reimbursement to cover pasteurized donor human milk, including human milk-based fortifiers, for premature infants weighing less than 3 lb 4 oz (1,500g). The measure was included as part of S. 2007, which was signed by Governor Cuomo last month. </p>]]></content> <dc:identifier>1221127</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Prolacta Bioscience</dc:contributor> <dc:modified>Tue, 05 Dec 2017 01:37 GMT</dc:modified> </entry> <entry> <id>https://www.globenewswire.com/news-release/2017/05/08/1221122/0/en/ConcertoHealth-R-Expands-Presence-in-Michigan-with-New-Clinical-and-Administration-Office-in-Kalamazoo.html</id> <title type="text">ConcertoHealth(R) Expands Presence in Michigan with New Clinical and Administration Office in Kalamazoo </title> <published>2017-05-08T13:05:00Z</published> <updated>2024-11-25T22:48:14Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2017/05/08/1221122/0/en/ConcertoHealth-R-Expands-Presence-in-Michigan-with-New-Clinical-and-Administration-Office-in-Kalamazoo.html" /> <content type="html"><![CDATA[<p><em><p>New Space Will Serve as Clinical Hub for ConcertoHealth's Primary Care Support Services in Southwest Michigan</p></em></p><p>KALAMAZOO, MI--(Marketwired - May 8, 2017) - <a rel="nofollow" href="http://www.concertohealthcare.com/" title="ConcertoHealth">ConcertoHealth</a>, the leading provider of specialized primary care and supporting clinical services for complex, frail, elderly and dual-eligible patients, is expanding its presence in Michigan with the opening of a new clinical and administrative office in Kalamazoo. The office will serve as the clinical hub for the company's innovative Primary Care Support Services model in the Southwest Michigan Region. </p>]]></content> <dc:identifier>1221122</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>ConcertoHealth</dc:contributor> <dc:modified>Tue, 05 Dec 2017 01:37 GMT</dc:modified> </entry> <entry> <id>https://www.globenewswire.com/news-release/2017/05/08/1221123/0/en/Prolacta-Bioscience-R-Launches-Nursing-Practice-Advisory-Council-and-Salutes-Neonatal-Nurses-and-Nurse-Practitioners-During-National-Nurse-Week.html</id> <title type="text">Prolacta Bioscience(R) Launches Nursing Practice Advisory Council and Salutes Neonatal Nurses and Nurse Practitioners During National Nurse Week </title> <published>2017-05-08T13:05:00Z</published> <updated>2024-11-25T22:48:14Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2017/05/08/1221123/0/en/Prolacta-Bioscience-R-Launches-Nursing-Practice-Advisory-Council-and-Salutes-Neonatal-Nurses-and-Nurse-Practitioners-During-National-Nurse-Week.html" /> <content type="html"><![CDATA[<p>DUARTE, CA--(Marketwired - May 8, 2017) - <a rel="nofollow" href="http://www.prolacta.com/" title="Prolacta Bioscience">Prolacta Bioscience</a>, the nation's leading provider of human milk-based neonatal nutritional products to hospitals, recognizes and honors the clinical expertise, dedication and commitment to care of neonatal nurses during National Nurse Week (May 6-12, 2017) with its support of four nursing conferences and the launch of a national Nursing Practice Advisory Council (NPAC). </p>]]></content> <dc:identifier>1221123</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Prolacta Bioscience</dc:contributor> <dc:modified>Tue, 05 Dec 2017 01:37 GMT</dc:modified> </entry> <entry> <id>https://www.globenewswire.com/news-release/2017/05/04/1221120/0/en/Refocus-Group-Concludes-12-Month-Follow-Up-for-Phase-3-Clinical-Trial-on-the-VisAbility-TM-Micro-Insert-System-for-Presbyopia-Readies-for-Pre-Market-Approval-Submission.html</id> <title type="text">Refocus Group Concludes 12-Month Follow-Up for Phase 3 Clinical Trial on the VisAbility(TM) Micro-Insert System for Presbyopia; Readies for Pre-Market Approval Submission </title> <published>2017-05-04T13:05:00Z</published> <updated>2024-11-25T22:48:14Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2017/05/04/1221120/0/en/Refocus-Group-Concludes-12-Month-Follow-Up-for-Phase-3-Clinical-Trial-on-the-VisAbility-TM-Micro-Insert-System-for-Presbyopia-Readies-for-Pre-Market-Approval-Submission.html" /> <content type="html"><![CDATA[<p><em><p>Research Spotlight May 8th at 2017 ASCRS ASOA Symposium & Congress</p></em></p><p>DALLAS, TX--(Marketwired - May 4, 2017) - <a rel="nofollow" href="http://refocus-group.com/" title="Refocus Group">Refocus Group</a>, a pioneer in vision-correcting technology, announced today that it has successfully completed its 12-month follow-up on 360 patients in its pivotal trial of the <a rel="nofollow" href="http://refocus-group.com/for-patients/visability-implant-for-presbyopia/" title="VisAbility™ Micro-Insert System">VisAbility™ Micro-Insert System</a> for presbyopia. The announcement paves the way for preparation of Refocus Group's Pre-Market Approval submission to the U.S. Food and Drug Administration (FDA). </p>]]></content> <dc:identifier>1221120</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Refocus Group</dc:contributor> <dc:modified>Tue, 05 Dec 2017 01:37 GMT</dc:modified> </entry> <entry> <id>https://www.globenewswire.com/news-release/2017/04/25/1221119/0/en/Ivantis-Announces-FDA-Clearance-to-Initiate-Clinical-Trial-of-the-Hydrus-TM-Microstent-for-Minimally-Invasive-Glaucoma-Surgery-MIGS-in-Patients-with-Advanced-Glaucoma.html</id> <title type="text">Ivantis Announces FDA Clearance to Initiate Clinical Trial of the Hydrus(TM) Microstent for Minimally Invasive Glaucoma Surgery (MIGS) in Patients with Advanced Glaucoma </title> <published>2017-04-25T12:05:00Z</published> <updated>2024-11-25T22:48:14Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2017/04/25/1221119/0/en/Ivantis-Announces-FDA-Clearance-to-Initiate-Clinical-Trial-of-the-Hydrus-TM-Microstent-for-Minimally-Invasive-Glaucoma-Surgery-MIGS-in-Patients-with-Advanced-Glaucoma.html" /> <content type="html"><![CDATA[<p>IRVINE, CA--(Marketwired - Apr 25, 2017) - <a rel="nofollow" href="http://www.ivantisinc.com/" title="Ivantis Inc.">Ivantis Inc.</a>, developer of the novel <a rel="nofollow" href="http://ivantisinc.com/hydrus-microstent.php" title="Hydrus™ Microstent">Hydrus™ Microstent</a> device, designed to lower eye pressure for glaucoma patients, announced today that the US Food and Drug Administration (FDA) has granted the company clearance to initiate a second investigational device exemption (IDE) clinical trial of the Hydrus Microstent. This trial will involve patients with advanced glaucoma, undergoing stand-alone glaucoma surgery without combined cataract surgery. </p>]]></content> <dc:identifier>1221119</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Ivantis Inc.</dc:contributor> <dc:modified>Tue, 05 Dec 2017 01:37 GMT</dc:modified> </entry> <entry> <id>https://www.globenewswire.com/news-release/2017/04/10/1221116/0/en/ConcertoHealth-R-Names-Kellie-J-Rice-Executive-Director-for-Michigan-Market.html</id> <title type="text">ConcertoHealth(R) Names Kellie J. Rice Executive Director for Michigan Market </title> <published>2017-04-10T13:05:00Z</published> <updated>2024-11-25T22:48:14Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2017/04/10/1221116/0/en/ConcertoHealth-R-Names-Kellie-J-Rice-Executive-Director-for-Michigan-Market.html" /> <content type="html"><![CDATA[<p>IRVINE, CA--(Marketwired - Apr 10, 2017) - <a rel="nofollow" href="http://www.concertohealthcare.com/" title="ConcertoHealth">ConcertoHealth</a>, the leading provider of specialized primary care and supporting clinical services for complex, frail, elderly and dual-eligible patients, has appointed Kellie J. Rice as executive director for its Michigan market, effective April 3, 2017. </p>]]></content> <dc:identifier>1221116</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>ConcertoHealth</dc:contributor> <dc:modified>Tue, 05 Dec 2017 01:36 GMT</dc:modified> </entry> <entry> <id>https://www.globenewswire.com/news-release/2017/03/30/1221114/0/en/Prolacta-Bioscience-R-Names-New-Nutrition-Advisory-Committee-Members-and-Expands-Resources-for-NICU-Dietitians-and-Clinicians.html</id> <title type="text">Prolacta Bioscience(R) Names New Nutrition Advisory Committee Members and Expands Resources for NICU Dietitians and Clinicians </title> <published>2017-03-30T13:05:00Z</published> <updated>2024-11-25T22:48:14Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2017/03/30/1221114/0/en/Prolacta-Bioscience-R-Names-New-Nutrition-Advisory-Committee-Members-and-Expands-Resources-for-NICU-Dietitians-and-Clinicians.html" /> <content type="html"><![CDATA[<p>DUARTE, CA--(Marketwired - Mar 30, 2017) - <a rel="nofollow" href="http://www.prolacta.com/" title="Prolacta Bioscience">Prolacta Bioscience</a><strong><sup>®</sup></strong>, the pioneer in human milk-based neonatal nutritional products for premature infants, today announced two new members of its Nutrition Advisory Committee (NAC): Keli Hawthorne, MS, RD, LD of Austin, Texas, and Carrie L. Petras, RD of Louisville, Ky.</p>]]></content> <dc:identifier>1221114</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Prolacta Bioscience</dc:contributor> <dc:modified>Tue, 05 Dec 2017 01:36 GMT</dc:modified> </entry> <entry> <id>https://www.globenewswire.com/news-release/2017/02/22/1221113/0/en/Prolacta-Bioscience-R-to-Present-at-the-Cowen-and-Company-37th-Annual-Health-Care-Conference-on-March-7th-2017.html</id> <title type="text">Prolacta Bioscience(R) to Present at the Cowen and Company 37th Annual Health Care Conference on March 7th, 2017 </title> <published>2017-02-22T14:05:00Z</published> <updated>2024-11-25T22:48:14Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2017/02/22/1221113/0/en/Prolacta-Bioscience-R-to-Present-at-the-Cowen-and-Company-37th-Annual-Health-Care-Conference-on-March-7th-2017.html" /> <content type="html"><![CDATA[<p>DUARTE, CA--(Marketwired - Feb 22, 2017) - Prolacta Bioscience<sup>®</sup> -- the nation's leading provider of human milk-based neonatal nutritional products, announced today that it will present at the Cowen and Company 37th Annual Health Care Conference in Boston, MA. Scott Elster, Prolacta's President and Chief Executive Officer, is scheduled to present on Tuesday, March 7, 2017 at 2:30 PM EST. </p>]]></content> <dc:identifier>1221113</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Prolacta Bioscience</dc:contributor> <dc:modified>Tue, 05 Dec 2017 01:36 GMT</dc:modified> </entry> <entry> <id>https://www.globenewswire.com/news-release/2017/02/17/1221111/0/en/Prolacta-Bioscience-R-to-Present-at-the-2017-RBC-Capital-Markets-Healthcare-Conference-on-February-22-2017.html</id> <title type="text">Prolacta Bioscience(R) to Present at the 2017 RBC Capital Markets Healthcare Conference on February 22, 2017 </title> <published>2017-02-17T14:05:00Z</published> <updated>2024-11-25T22:48:14Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2017/02/17/1221111/0/en/Prolacta-Bioscience-R-to-Present-at-the-2017-RBC-Capital-Markets-Healthcare-Conference-on-February-22-2017.html" /> <content type="html"><![CDATA[<p>DUARTE, CA--(Marketwired - Feb 17, 2017) - Prolacta Bioscience<sup>®</sup> -- the nation's leading provider of human milk-based neonatal nutritional products, announced today that it will present at the 2017 RBC Capital Markets Healthcare Conference in New York, NY. Scott Elster, Prolacta's President and Chief Executive Officer, is scheduled to present on Wednesday, February 22, 2017 at 11:20 AM EST. </p>]]></content> <dc:identifier>1221111</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Prolacta Bioscience</dc:contributor> <dc:modified>Tue, 05 Dec 2017 01:36 GMT</dc:modified> </entry> <entry> <id>https://www.globenewswire.com/news-release/2017/02/16/1221109/0/en/Prolacta-Bioscience-R-Initiates-Clinical-Trial-to-Evaluate-the-Effect-of-a-Specially-Fortified-Exclusive-Human-Milk-Diet-to-Improve-Growth-in-Infants-Born-with-Single-Ventricle-Con.html</id> <title type="text">Prolacta Bioscience(R) Initiates Clinical Trial to Evaluate the Effect of a Specially Fortified Exclusive Human Milk Diet to Improve Growth in Infants Born with Single Ventricle Congenital Heart Defect </title> <published>2017-02-16T14:05:00Z</published> <updated>2024-11-25T22:48:14Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2017/02/16/1221109/0/en/Prolacta-Bioscience-R-Initiates-Clinical-Trial-to-Evaluate-the-Effect-of-a-Specially-Fortified-Exclusive-Human-Milk-Diet-to-Improve-Growth-in-Infants-Born-with-Single-Ventricle-Con.html" /> <content type="html"><![CDATA[<p>DUARTE, CA--(Marketwired - Feb 16, 2017) - Prolacta Bioscience<sup>®</sup>, the pioneer in human milk-based neonatal nutritional products, announced today that the first patient has been enrolled in a clinical study to evaluate the effect of a specially fortified exclusive human milk diet (EHMD)<sup>1</sup> to improve growth in infants who have undergone surgery for a serious heart defect known as single ventricle cardiac physiology. Prolacta developed a first-of-its-kind, human milk-based fortifier to address the post-surgical nutrition needs of this fragile infant population. </p>]]></content> <dc:identifier>1221109</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Prolacta Bioscience</dc:contributor> <dc:modified>Tue, 05 Dec 2017 01:36 GMT</dc:modified> </entry> <entry> <id>https://www.globenewswire.com/news-release/2017/02/01/1221107/0/en/Open-Call-for-Entries-for-the-Ruth-A-Lawrence-Investigator-Award-for-Research-in-Human-Milk-Science.html</id> <title type="text">Open Call for Entries for the Ruth A. Lawrence Investigator Award for Research in Human Milk Science </title> <published>2017-02-01T15:00:00Z</published> <updated>2024-11-25T22:48:14Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2017/02/01/1221107/0/en/Open-Call-for-Entries-for-the-Ruth-A-Lawrence-Investigator-Award-for-Research-in-Human-Milk-Science.html" /> <content type="html"><![CDATA[<p>PASADENA, CA--(Marketwired - Feb 1, 2017) - The International Conference on Human Milk Science and Innovation (ICHMSI) announced today that applications are now being accepted for the Ruth A. Lawrence Investigator Award for Research in Human Milk Science. The award was created to encourage original research in the area of human milk science and breastfeeding medicine, and to support the advancement of emerging researchers in this vital area of science. Entries are due by June 1, 2017. </p>]]></content> <dc:identifier>1221107</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Human Milk Science and Innovation Conference</dc:contributor> <dc:modified>Tue, 05 Dec 2017 01:36 GMT</dc:modified> </entry> <entry> <id>https://www.globenewswire.com/news-release/2017/01/24/1221105/0/en/ConcertoHealth-R-Names-Chrissie-Cooper-Chief-Operating-Officer.html</id> <title type="text">ConcertoHealth(R) Names Chrissie Cooper Chief Operating Officer </title> <published>2017-01-24T14:07:00Z</published> <updated>2024-11-25T22:48:14Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2017/01/24/1221105/0/en/ConcertoHealth-R-Names-Chrissie-Cooper-Chief-Operating-Officer.html" /> <content type="html"><![CDATA[<p>IRVINE, CA--(Marketwired - Jan 24, 2017) - <a rel="nofollow" href="http://www.concertohealthcare.com/" title="ConcertoHealth">ConcertoHealth</a>, the nation's leading provider of healthcare services for complex, frail, elderly, and dual-eligible patients, today announced the appointment of Chrissie Cooper as chief operating officer. Bringing two decades of medical group and health plan leadership experience, Cooper will lead ConcertoHealth's market operations as it expands its unique care model and value-based care-enabling technology platform to provider networks nationwide.</p>]]></content> <dc:identifier>1221105</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>ConcertoHealth</dc:contributor> <dc:modified>Tue, 05 Dec 2017 01:36 GMT</dc:modified> </entry> <entry> <id>https://www.globenewswire.com/news-release/2017/01/09/1221103/0/en/Ivantis-Raises-25-Million-Series-C-to-Fund-Future-US-Commercialization-of-the-Hydrus-TM-Microstent-for-Minimally-Invasive-Glaucoma-Surgery-MIGS.html</id> <title type="text">Ivantis Raises $25 Million Series C to Fund Future US Commercialization of the Hydrus(TM) Microstent for Minimally Invasive Glaucoma Surgery (MIGS) </title> <published>2017-01-09T14:05:00Z</published> <updated>2024-11-25T22:48:14Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2017/01/09/1221103/0/en/Ivantis-Raises-25-Million-Series-C-to-Fund-Future-US-Commercialization-of-the-Hydrus-TM-Microstent-for-Minimally-Invasive-Glaucoma-Surgery-MIGS.html" /> <content type="html"><![CDATA[<p>IRVINE, CA--(Marketwired - Jan 9, 2017) - <a rel="nofollow" href="http://www.ivantisinc.com/" title="Ivantis Inc.">Ivantis Inc.</a>, developer of the novel Hydrus™ Microstent device designed to lower eye pressure for glaucoma patients, announced today that it closed a $25 million Series C financing. The round was led by new investor RA Capital Management, and included new investor Mérieux Développement, as well as existing investors. The funds will extend Ivantis' runway into 2020 and will support US commercialization of the Hydrus Microstent upon its anticipated 2018 US Food and Drug Administration (FDA) Approval.</p>]]></content> <dc:identifier>1221103</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Ivantis, Inc.</dc:contributor> <dc:modified>Tue, 05 Dec 2017 01:36 GMT</dc:modified> </entry> <entry> <id>https://www.globenewswire.com/news-release/2016/12/09/1221101/0/en/Parcel-Pending-Voted-One-of-Orange-County-s-Top-Places-to-Work.html</id> <title type="text">Parcel Pending Voted One of Orange County's Top Places to Work </title> <published>2016-12-09T14:15:00Z</published> <updated>2024-11-25T22:48:14Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2016/12/09/1221101/0/en/Parcel-Pending-Voted-One-of-Orange-County-s-Top-Places-to-Work.html" /> <content type="html"><![CDATA[<p><em><p>Nationally-Recognized Company Named a Leading Employer in Orange County Register's 2016 Top Workplaces Report</p></em></p><p>IRVINE, CA--(Marketwired - Dec 9, 2016) - <a rel="nofollow" href="http://parcelpending.com/" title="Parcel Pending">Parcel Pending</a>, the nation's leading package management company with <em>100% Always-On Customer Service</em>®, recently was named one of the best places to work in Orange County, CA according to the 2016 Top Workplaces report published annually by the <em>Orange County Register.</em> The countywide survey recognizes local companies that have had a measurable and meaningful impact on employees in the past year. </p>]]></content> <dc:identifier>1221101</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Parcel Pending</dc:contributor> <dc:modified>Tue, 05 Dec 2017 01:36 GMT</dc:modified> </entry> <entry> <id>https://www.globenewswire.com/news-release/2016/12/06/1221099/0/en/UPDATE-Prolacta-Bioscience-R-Raises-35-Million-in-Mezzanine-Financing.html</id> <title type="text">UPDATE - Prolacta Bioscience(R) Raises $35 Million in Mezzanine Financing </title> <published>2016-12-06T21:36:49Z</published> <updated>2024-11-25T22:48:14Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2016/12/06/1221099/0/en/UPDATE-Prolacta-Bioscience-R-Raises-35-Million-in-Mezzanine-Financing.html" /> <content type="html"><![CDATA[<p>CITY OF INDUSTRY, CA--(Marketwired - Dec 6, 2016) - Prolacta Bioscience<sup>®</sup>, the nation's leading provider of human milk-based neonatal nutritional products, today announced the closing of a $35 million mezzanine round of financing. The transaction was led by Essex Woodlands and included participation from Aisling Capital, with existing shareholder Health Evolution Partners. As part of the transaction, Martin Sutter, Co-Founder and Managing Director at Essex Woodlands, will join Prolacta's Board of Directors. </p>]]></content> <dc:identifier>1221099</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Prolacta Bioscience</dc:contributor> <dc:modified>Tue, 05 Dec 2017 01:36 GMT</dc:modified> </entry> <entry> <id>https://www.globenewswire.com/news-release/2016/12/06/1221095/0/en/Parcel-Pending-Announces-New-Chief-Operating-Officer-and-Vice-President-of-Sales.html</id> <title type="text">Parcel Pending Announces New Chief Operating Officer and Vice President of Sales </title> <published>2016-12-06T14:05:00Z</published> <updated>2024-11-25T22:48:14Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2016/12/06/1221095/0/en/Parcel-Pending-Announces-New-Chief-Operating-Officer-and-Vice-President-of-Sales.html" /> <content type="html"><![CDATA[<p><em><p>Brad Farmer Joins as COO; Matt Haynes Named VP Sales</p></em></p><p>IRVINE, CA--(Marketwired - Dec 6, 2016) - <a rel="nofollow" href="http://parcelpending.com/" title="Parcel Pending">Parcel Pending</a>, the nation's leading package management company with <em>100% Always-On Customer Service</em><sup>®</sup>, announced today the addition of two executives to its leadership team: Chief Operating Officer Brad Farmer and Vice President of Sales Matt Haynes. They bring a combined 40 years experience, driving revenue growth and managing infrastructures for emerging companies. </p>]]></content> <dc:identifier>1221095</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Parcel Pending</dc:contributor> <dc:modified>Tue, 05 Dec 2017 01:36 GMT</dc:modified> </entry> </feed>